Shots:

• The 18mos. alliance will support two studies that will evaluate clinical tools- include proteomics & digital health for Lupus management in the US
• The 1st study will evaluate the impact of the aisle MGMT platform on the clinical process to support personalized care & prevention or reduction in the severity of lupus flares. The 2nd OASIS study will investigate PROs and data from a wearable device to support the development of lupus-specific digital biomarkers and deliver insight for change in lupus disease activity
• Both studies are expected to initiate in 2021 & results will be submitted for presentation at scientific congresses & manuscripts for publication in peer-reviewed journals

  Ref: PR Newswire | Image: GSK